Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Spero Therapeutics Inc (NQ: SPRO )

1.330 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.330
Bid (Size) 1.350 (7)
Ask (Size) 1.480 (10)
Prev. Close 1.330
Today's Range 1.330 - 1.330
52wk Range 0.9900 - 1.890
Shares Outstanding 52,571,813
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
SPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
3 Micro-Cap Moonshots for Fearless Investors
Investors should know the risks of micro-cap stocks before looking into these three high-potential companies with low prices. 
Via InvestorPlace

Performance

YTD
-12.50%
-12.50%
1 Month
+4.72%
+4.72%
3 Month
+4.72%
+4.72%
6 Month
-25.28%
-25.28%
1 Year
+6.40%
+6.40%

More News

Read More
SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Recap: Spero Therapeutics Q4 Earnings
Via Benzinga
Earnings Outlook For Spero Therapeutics
Via Benzinga
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Recap: Spero Therapeutics Q3 Earnings
Via Benzinga
Earnings Outlook For Spero Therapeutics
Via Benzinga
4 Analysts Have This to Say About Spero Therapeutics
Via Benzinga
Earnings Scheduled For March 13, 2024
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Spero Therapeutics's Earnings: A Preview
Via Benzinga
Recap: Spero Therapeutics Q1 Earnings
Via Benzinga
Spero Therapeutics's Earnings Outlook
Via Benzinga
Earnings Scheduled For November 13, 2023
Via Benzinga
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To Know
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Earnings Scheduled For August 10, 2023
Via Benzinga
Earnings Scheduled For May 11, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.